Neoplasms

Respiratory Tract (Lung and Bronchial) Diseases

All Conditions

Behaviors and Mental Disorders

Lung Neoplasms

Carcinoma, Non-Small-Cell Lung

Carcinoma

Respiratory Tract Neoplasms

Thoracic Neoplasms

Lung Diseases

Respiratory Tract Diseases

Carcinoma, Bronchogenic

Bronchial Neoplasms

Quality of Life

Stage II patients treated with surgery alone

Stage III patients treated with surgery and PORT

Krzysztof Bujko, Prof.

The patients from 12 centers were included into the study. pN2 patients received PORT, pN1 patients did not. PORT was 3D-planned and consisted in 54-56 Gy in 27-28 fractions. One month after surgery, all patients completed EORTC QLQ C-30 questionnaires and had pulmonary function tests (PFT); cardiopulmonary symptoms were assessed by modified LENT-SOM score. Two years after, all patients free of disease repeated the same examinations. Changes in QLQ, LENT-SOM score and the results of PFT were compared for patients receiving and not PORT.

Prospective Study of Quality of Life in Non-small Cell Lung Cancer (NSCLC) Patients Treated With/Without Postoperative Radiotherapy

Prospective Comparison of Quality of Life and Cardiopulmonary Morbidity After Surgery in Non-small Cell Lung Cancer Patients Treated With and Without Postoperative Radiotherapy

All patients had pulmonary function tests (PFT) with Forced Vital Capacity (FVC) and Forced Expiratory Volume in 1 Second (FEV1) recorded.

For quality of life assessment, patients were asked to complete the Quality of Life Questionnaire Core 30 Items (QLC-C30) of the European Organization for Research and Treatment of Cancer (EORTC).

Institute of Tuberculosis and Lung Diseases in Warsaw

The Greater Poland Centre of Lung Diseases and Tuberculosis in Poznan

The Greater Poland Cancer Centre

Cancer Centre in Bydgoszcz

Kujawsko-Pomorskie Center of Pulmonology in Bydgoszcz

Specialized Hospital in Zdunowo - Szczecin

Regional Cancer Hospital - Szczecin

Medical University of Gdansk

Holycross Cancer Center in Kielce

Department of Thoracic Surgery - Wrocław

Department of Radiotherapy - Olsztyn

Department of Thoracic Surgery - Łódź

Lower Silesian Oncology Center - Wroclaw

Regional Specialized Hospital -Chęciny, Czerwona Góra

Department of Thoracic Surgery - Otwock

Medical University of Łódź

Maria Sklodowska-Curie National Research Institute of Oncology

Prof Krzysztof Bujko

Adult patients, with confirmed diagnosis of BRAF V600E mutant advanced or metastatic NSCLC who have progressed on or after at least one prior systemic anticancer therapy.

LGX818

Pfizer CT.gov Call Center

This is an open-label, multi-center, single arm phase II study to evaluate the efficacy and safety of novel BRAF (B-raf murine sarcoma viral oncogene homolog B1) inhibitor encorafenib (LGX818) when used as single agent in patients with advanced or metastatic (stage IIIB or IV) BRAF V600 mutant NSCLC. Patients must have progressed on or after at least one previous systemic, anti-cancer therapy for locally advanced or metastatic NSCLC.

Efficacy and Safety of LGX818 in Patients With Advanced or Metastatic BRAF V600 Mutant NSCLC

A Phase II, Single Arm, Open-label, Multicenter, Study of Oral LGX818 in Patients With BRAF V600 Mutant, Advanced Non-small Cell Lung Cancer (NSCLC) That Have Progressed During or After at Least One Prior Chemotherapy

ORR per Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 as assessed by investigator

ORR per RECIST 1.1 as assessed by by Blinded independent review committee (BIRC)

DOR by investigator and BIRC assessments.

Adverse events and laboratory abnormalities

DCR by investigator and BIRC assessments.

Plasma concentration-time profiles of encorafenib (LGX818).

Concordance rate between BRAF mutation status obtained using the investigational diagnostic test and the companion diagnostic assay which will be submitted for Pre-market approval (PMA)

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Prospective Study of Quality of Life in Non-small Cell Lung Cancer (NSCLC) Patients Treated With/Without Postoperative Radiotherapy	NCT01112631	Non-Small Cell ...		18 Years -	Maria Sklodowska-Curie National Research Institute of Oncology
Efficacy and Safety of LGX818 in Patients With Advanced or Metastatic BRAF V600 Mutant NSCLC	NCT02109653	Non-Small Cell ...	LGX818	18 Years -	Array BioPharma

Spots Global Cancer Trial Database for nsclc,

Every month we try and update this database with for nsclc, cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for nsclc,

Every month we try and update this database with for nsclc, cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for nsclc, cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.